Susquehanna International Group
TEVA icon

Susquehanna International Group’s Teva Pharmaceuticals TEVA Stock Holding History

Susquehanna International Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$155M Sell
5,152,000
-562,000
-10% -$18.1M 0.02% 617
2025
Q4 		$178M Buy
5,714,000
+1,203,000
+27% +$29.6M 0.02% 579
2025
Q3 		$91.1M Buy
4,511,000
+874,400
+24% +$15.4M 0.01% 950
2025
Q2 		$60.9M Sell
3,636,600
-967,800
-21% -$15.6M 0.01% 1043
2025
Q1 		$70.8M Buy
4,604,400
+2,443,600
+113% +$43.6M 0.01% 826
2024
Q4 		$47.6M Buy
2,160,800
+624,400
+41% +$11.4M 0.01% 1155
2024
Q3 		$27.7M Buy
1,536,400
+154,300
+11% +$2.7M ﹤0.01% 1530
2024
Q2 		$22.5M Sell
1,382,100
-1,848,500
-57% -$28.5M ﹤0.01% 1614
2024
Q1 		$45.6M Buy
3,230,600
+703,400
+28% +$8.87M 0.01% 1097
2023
Q4 		$26.4M Sell
2,527,200
-890,900
-26% -$8.32M 0.01% 1518
2023
Q3 		$34.9M Sell
3,418,100
-1,464,000
-30% -$13.6M 0.01% 1262
2023
Q2 		$36.8M Buy
4,882,100
+232,300
+5% +$1.88M 0.01% 1204
2023
Q1 		$41.2M Sell
4,649,800
-745,100
-14% -$7.37M 0.01% 1074
2022
Q4 		$49.2M Buy
5,394,900
+30,600
+0.6% +$267K 0.01% 887
2022
Q3 		$43.3M Sell
5,364,300
-296,600
-5% -$2.62M 0.01% 887
2022
Q2 		$42.6M Sell
5,660,900
-2,027,000
-26% -$17.7M 0.01% 936
2022
Q1 		$72.2M Sell
7,687,900
-2,687,600
-26% -$22.4M 0.01% 817
2021
Q4 		$83.1M Sell
10,375,500
-503,900
-5% -$4.55M 0.01% 803
2021
Q3 		$106M Buy
10,879,400
+275,900
+3% +$2.58M 0.01% 762
2021
Q2 		$105M Buy
10,603,500
+1,160,000
+12% +$12.3M 0.01% 765
2021
Q1 		$109M Buy
9,443,500
+542,600
+6% +$6.22M 0.02% 683
2020
Q4 		$85.9M Buy
8,900,900
+1,893,600
+27% +$18.1M 0.01% 727
2020
Q3 		$63.1M Sell
7,007,300
-816,100
-10% -$8.63M 0.01% 756
2020
Q2 		$96.5M Sell
7,823,400
-4,311,400
-36% -$48.8M 0.02% 514
2020
Q1 		$109M Buy
12,134,800
+1,438,500
+13% +$14.7M 0.03% 360
2019
Q4 		$105M Buy
10,696,300
+621,400
+6% +$5.55M 0.03% 464
2019
Q3 		$69.3M Buy
10,074,900
+2,495,600
+33% +$19.1M 0.02% 580
2019
Q2 		$70M Buy
7,579,300
+1,023,900
+16% +$12.3M 0.03% 539
2019
Q1 		$103M Sell
6,555,400
-734,100
-10% -$12.9M 0.04% 364
2018
Q4 		$112M Buy
7,289,500
+437,300
+6% +$8.96M 0.04% 347
2018
Q3 		$148M Buy
6,852,200
+744,000
+12% +$17.3M 0.05% 323
2018
Q2 		$149M Sell
6,108,200
-1,184,900
-16% -$24.2M 0.05% 303
2018
Q1 		$125M Sell
7,293,100
-2,420,900
-25% -$47.3M 0.04% 327
2017
Q4 		$184M Sell
9,714,000
-994,800
-9% -$15M 0.06% 260
2017
Q3 		$188M Buy
10,708,800
+4,673,000
+77% +$105M 0.07% 219
2017
Q2 		$201M Buy
6,035,800
+596,900
+11% +$18.5M 0.09% 192
2017
Q1 		$175M Sell
5,438,900
-294,400
-5% -$10M 0.09% 196
2016
Q4 		$208M Buy
5,733,300
+968,500
+20% +$38.7M 0.11% 165
2016
Q3 		$219M Buy
4,764,800
+1,124,300
+31% +$58.7M 0.11% 147
2016
Q2 		$183M Buy
3,640,500
+155,200
+4% +$8.26M 0.1% 174
2016
Q1 		$186M Buy
3,485,300
+422,500
+14% +$24.8M 0.1% 157
2015
Q4 		$201M Sell
3,062,800
-1,216,900
-28% -$75.2M 0.09% 183
2015
Q3 		$242M Buy
4,279,700
+232,800
+6% +$15.1M 0.1% 162
2015
Q2 		$239M Buy
4,046,900
+364,100
+10% +$22.5M 0.1% 162
2015
Q1 		$229M Buy
3,682,800
+281,600
+8% +$16.4M 0.1% 166
2014
Q4 		$196M Sell
3,401,200
-262,300
-7% -$14.6M 0.08% 238
2014
Q3 		$197M Sell
3,663,500
-377,800
-9% -$20M 0.08% 220
2014
Q2 		$212M Sell
4,041,300
-1,732,900
-30% -$88.6M 0.09% 174
2014
Q1 		$305M Sell
5,774,200
-1,046,000
-15% -$48.3M 0.14% 106
2013
Q4 		$273M Buy
6,820,200
+3,750,900
+122% +$148M 0.13% 113
2013
Q3 		$116M Buy
3,069,300
+251,900
+9% +$9.83M 0.06% 270
2013
Q2 		$110M Buy
+2,817,400
New +$110M 0.06% 240

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's TEVA Position: Q1 2026 in Review

Susquehanna International Group increased its Teva Pharmaceuticals (TEVA) stake by 877% in Q1 2026, buying an estimated $21.4M and bringing the position to 739,515 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

Susquehanna International Group first reported a position in TEVA in Q2 2013 and has held it in 49 quarters since. The position peaked at $154M in Q3 2016. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Susquehanna International Group held 739,515 shares of Teva Pharmaceuticals worth $22.3M as of Q1 2026.
  • Susquehanna International Group bought 663,802 Teva Pharmaceuticals shares in Q1 2026, an estimated $21.4M.
  • Teva Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2091 holding.
  • Susquehanna International Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Susquehanna International Group's Teva Pharmaceuticals position peaked at $154M in Q3 2016.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.